Providing Patients with an Improved Alternative to Irinotecan
PCS11T Targets Various Types of Cancer
Processa Pharmaceuticals is developing PCS11T as a novel prodrug alternative to irinotecan, a second-line therapy for many types of cancer (e.g., metastatic colorectal, small cell lung, and pancreatic). Irinotecan is widely recognized as a potent anti-cancer agent, but it comes with significant drawbacks, including a narrow therapeutic window and severe, dose-limiting side effects like bone marrow suppression and severe diarrhea. PCS11T combines SN-38, the active, anti-cancer moiety in irinotecan, with an additional moiety that slows the release of SN-38 and allows it to preferentially accumulate in tumor cells, capturing them in their vulnerable S phase for eradication.
In May 2020, we entered into an exclusive License Agreement with Aposense, Ltd. (Aposense) in which we acquired a contingent license in Aposense's patent rights and know-how to develop and commercialize PCS11T. The license was conditioned on approval from the Israel Innovation Authority, and successful up-listing to Nasdaq—conditions that have been met.